Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants (opens ClinicalTrials.gov)
- Sponsor
- Gan and Lee Pharmaceuticals, USA
- Enrolment
- 326
- Started
- 2025-02-24
- Last update
- 2026-07-16
Conditions: Obesity and Overweight
Interventions: GZR18, Tirzepatide